Nurix Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 27.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.96B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Details
| Name | Nurix Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 317 |
| Founded | 2009 |
| Ipo Date | 2020-07-24 |
| Ceo | Arthur Sands |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US67080M1036 |
| Cusip | 67080M103 |
| Cik | 1549595 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President and Director |
| Johannes Van Houte | Chief Financial Officer |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary and Chief Compliance Officer |
| Dr. John Kuriyan Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Arthur Weiss M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Rita Kwong | Senior Accounting Manager |
| Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer |
| Wesley Burwell | Chief Human Resources Officer |
| Dr. Jason Kantor Ph.D. | Chief Business Officer |
Contact
| Address | 1600 Sierra Point Parkway, Brisbane, California 94005, United States |
| Phone | 415 660 5320 |
| Website | https://www.nurixtx.com |